Announcements Trials
Browse Landscape

Phase

Phase 1 41Phase 2 26Phase 1/2 9Phase 3 4Phase 4 2Phase EARLY_PHASE1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 6Lymphoid 4Tumor-Agnostic 2Genitourinary 2Myeloid 1Head & Neck 1

Conditions

Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Drug Therapy 5Docetaxel 3Bevacizumab 3icotinib 2Vincristine 2Pemetrexed 2Misoprostol 2Genes, p53 2Gemcitabine 2Dexamethasone 2Carboplatin 2Aspirin 2pinaverium 1pentetreotide 1pembrolizumab 1pazopanib 1olaparib 1netupitant, palosentron drug combination 1nedaplatin 1lorlatinib 1durvalumab 1ceritinib 1atezolizumab 1Zoledronic Acid 1Water 1Vitamin E 1Vemurafenib 1Ultracet 1Triamcinolone 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Gemcitabine × Tumor-Agnostic × Clear all
NCT06820255 2025-02-11

SELECTIO-UC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 4 Recruiting
135 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02194556 2014-07-18

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Betta Pharmaceuticals Co., Ltd.

Phase 4 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡